Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in R/R AML
NCT07783100Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, tucidinostat, chiglitazar in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Started Nov 2026; status: recruiting.
02
Drugs
venetoclaxtucidinostatchiglitazar
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07783100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783100.